Skip to main content
. 2022 May 20;19(8):533–550. doi: 10.1038/s41575-022-00608-8

Fig. 5. Evolution of HCV therapy.

Fig. 5

There has been a continuous increase in sustained virological response rates over time, starting with only 6–19% when using the first interferon-α (IFN) monotherapies to cure rates of >98% in the era of direct-acting antiviral agents (DAAs)5,65,66,71,73,117,119,146,152,266. HCV, hepatitis C virus; Peg-IFN, pegylated interferon-α; PI, protease inhibitor; RBV, ribavirin.